Stryker (SYK) Stock Forecast & Price Target

Q: What analysts cover Stryker?

Stryker has been rated by research analysts at Argus , BMO Capital Markets , BTIG Research , Canaccord Genuity Group , Citigroup , Citizens Jmp , Evercore , JPMorgan Chase & Co. , Piper Sandler , Raymond James Financial , Royal Bank Of Canada , TD Cowen , Truist Financial , UBS Group , Weiss Ratings , Wells Fargo & Company , and Wolfe Research in the past 90 days.

$275.57 +3.21 (+1.18%)

Closing price 03:59 PM Eastern

Extended Trading

$276.21 +0.64 (+0.23%)

As of 07:41 PM Eastern

Compare

Stryker - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Moderate Buy

Based on 23 Analyst Ratings

Sell
0

Hold
5

Buy
18

Based on 23 Wall Street analysts who have issued ratings for Stryker in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 23 analysts, 5 have given a hold rating, and 18 have given a buy rating for SYK.

Consensus Price Target

$374.42
35.87% Upside

According to the 23 analysts' twelve-month price targets for Stryker, the average price target is $374.42. The highest price target for SYK is $465.00, while the lowest price target for SYK is $298.00. The average price target represents a forecasted upside of 35.87% from the current price of $275.57.

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Get the Latest News and Ratings for SYK and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Stryker and its competitors.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

SYK Analyst Ratings Over Time

Type	Current Forecast 9/28/25 to 9/28/26	1 Month Ago 8/29/25 to 8/29/26	3 Months Ago 6/30/25 to 6/30/26	1 Year Ago 9/28/24 to 9/28/25
Strong Buy	0 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	18 Buy rating(s)	17 Buy rating(s)	16 Buy rating(s)	15 Buy rating(s)
Hold	5 Hold rating(s)	6 Hold rating(s)	6 Hold rating(s)	5 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$374.42	$386.28	$395.33	$430.85
Forecasted Upside	35.87% Upside	16.59% Upside	25.58% Upside	16.82% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

SYK Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

SYK Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Stryker Stock vs. The Competition

Type	Stryker	Healthcare Companies	Broader Market
Consensus Rating Score	2.78	2.31	2.53
Consensus Rating	Moderate Buy	Hold	Moderate Buy
Predicted Upside	35.87% Upside	780.15% Upside	19.96% Upside
News Sentiment Rating	Positive News See Recent SYK News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
9/22/2026	TD Cowen 3 of 5 stars	Mathew Blackman Not Rated	Lower Target	Hold	$355.00 ➝ $298.00	+8.88%
9/18/2026	Canaccord Genuity Group 3 of 5 stars	Kyle Rose 2 of 5 stars	Lower Target	Buy	$400.00 ➝ $385.00	+37.32%
9/10/2026	Citigroup 4 of 5 stars	Joanne Wuensch 2 of 5 stars	Lower Target	Buy	$399.00 ➝ $360.00	+31.42%
9/9/2026	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Outperform	$317.00	+14.21%
9/9/2026	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Larry Biegelsen Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Overweight	$418.00 ➝ $348.00	+26.02%
8/13/2026	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Mike Polark Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Downgrade	Outperform ➝ Peer Perform
8/3/2026	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	David Turkaly Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Market Outperform	$440.00 ➝ $400.00	+19.13%
7/31/2026	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Hold (C)
7/31/2026	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Kendall Au Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Outperform	$435.00 ➝ $420.00	+30.93%
7/31/2026	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Set Target		$370.00	+15.35%
Get the Latest News and Ratings for SYK and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Stryker and its competitors with MarketBeat's FREE daily newsletter.
7/31/2026	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Matt O'Brien Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Overweight	$420.00 ➝ $390.00	+11.95%
7/31/2026	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Robbie Marcus Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Overweight	$400.00 ➝ $350.00	+7.71%
7/31/2026	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Richard Newitter Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Hold	$330.00 ➝ $340.00	+5.29%
7/31/2026	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Ryan Zimmerman Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Buy	$371.00 ➝ $358.00	+2.76%
7/28/2026	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Danielle Antalffy Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	Buy	$400.00	+18.58%
7/9/2026	Argus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Set Target		$370.00	+12.96%
7/6/2026	Evercore Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Set Target		$350.00	+8.72%
6/5/2026	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Mike Kratky Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Outperform	$410.00 ➝ $407.00	+35.30%
5/4/2026	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Matt Miksic Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Overweight	$469.00 ➝ $394.00	+33.36%
5/1/2026	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	David Roman Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Neutral	$361.00	+22.19%
5/1/2026	Sanford C. Bernstein Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Set Target		$410.00	+35.16%
5/1/2026	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Set Target		$385.00	+27.40%
5/1/2026	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Set Target		$315.00	+1.65%
5/1/2026	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Mike Matson Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Buy	$454.00 ➝ $418.00	+32.85%
3/5/2026	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Outperform
3/4/2026	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Matthew Taylor Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Buy	$465.00	+21.57%
9/18/2025	Rothschild & Co Redburn Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Set Target		$420.00	+11.54%
5/2/2025	Roth Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Jason Wittes Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$405.00 ➝ $456.00	+20.75%
1/29/2025	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Rick Wise Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$400.00 ➝ $440.00	+11.41%
12/2/2024	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Equal Weight ➝ Overweight	$370.00 ➝ $445.00	+13.48%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 09:51 PM ET.

Should I Buy Stryker Stock? SYK Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Friday, September 25, 2026. Please send any questions or comments about these Stryker pros and cons to contact@marketbeat.com.

Stryker
Bull Case

Here are some ways that investors could benefit from investing in Stryker Co.:

Stryker Co. recently reported strong financial performance in its most recent quarter, beating consensus estimates with earnings per share of $3.69 compared to the expected $3.49, while also achieving revenue of $6.59 billion, which exceeded the $6.58 billion forecast and represented a 9.4% year-over-year increase.
The company maintains a favorable valuation profile with a current stock price of $272.11, which is significantly below the consensus price target of $380.40, suggesting substantial potential upside for investors as the stock trades at a P/E ratio of 28.20.
Stryker Co. offers a stable income stream through its dividend, which has a yield of 1.28% and a payout ratio of 36.48%, indicating that the company retains a significant portion of its earnings for reinvestment while still providing regular cash returns to shareholders.
The stock exhibits lower volatility than the broader market with a beta of 0.76, making it a potentially defensive holding for investors seeking to reduce portfolio risk while maintaining exposure to the healthcare sector.
Institutional investors continue to show confidence in the company, with Envestnet Asset Management Inc. increasing its position by 12.2% in the second quarter and State Street Corp raising its stake by 1.2%, reflecting ongoing institutional support for Stryker Co.

Stryker
Bear Case

Investors should be bearish about investing in Stryker Co. for these reasons:

Stryker Co. is facing legal scrutiny, with Pomerantz LLP and Block & Leviton investigating claims on behalf of investors for potential securities law violations, which could lead to significant financial liabilities and reputational damage.
The company disclosed persisting peripheral vascular manufacturing issues that were previously thought to be resolved, causing an 8.8% drop in the stock price on September 8, 2026, and raising concerns about operational execution and product quality.
Analysts have recently lowered their price targets for Stryker Co., with Raymond James cutting its target from $370 to $330 and Canaccord Genuity Group reducing its target from $400 to $385, reflecting a more cautious outlook on the company's near-term growth prospects.
Insider selling has been significant, with corporate insiders selling 351,267 shares worth approximately $118.2 million over the last 90 days, including large sales by Director Ronda E Stryker, which may signal a lack of confidence from those with the most knowledge of the company.
The stock is trading near its 52-week low of $267.00, having declined from a high of $392.55, indicating a sustained downward trend and potential continued pressure on the share price as it approaches support levels.

SYK Forecast - Frequently Asked Questions

According to the research reports of 23 Wall Street equities research analysts, the average twelve-month stock price forecast for Stryker is $374.42, with a high forecast of $465.00 and a low forecast of $298.00.

23 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Stryker in the last twelve months. There are currently 5 hold ratings and 18 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" SYK shares.

According to analysts, Stryker's stock has a predicted upside of 35.87% based on their 12-month stock forecasts.

Over the previous 90 days, Stryker's stock had 1 upgrade and 1 downgrade by analysts.

Stryker has been rated by research analysts at Argus, BMO Capital Markets, BTIG Research, Canaccord Genuity Group, Citigroup, Citizens Jmp, Evercore, JPMorgan Chase & Co., Piper Sandler, Raymond James Financial, Royal Bank Of Canada, TD Cowen, Truist Financial, UBS Group, Weiss Ratings, Wells Fargo & Company, and Wolfe Research in the past 90 days.

Analysts like Stryker more than other "healthcare" companies. The consensus rating for Stryker is Moderate Buy while the average consensus rating for "healthcare" companies is Hold. Learn more on how SYK compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Stryker Recommendations

MarketBeat monitors more than a dozen sources for Stryker analyst ratings, with the most recent rating issued on 9/22/2026.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Stryker (SYK) Stock Forecast & Price Target